Status:

NOT_YET_RECRUITING

To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture

Lead Sponsor:

Qilu Pharmaceutical Co., Ltd.

Conditions:

Postmenopausal Women With Osteoporosis

Eligibility:

All Genders

50-85 years

Phase:

PHASE3

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of QLG2128 in the treatment of postmenopausal women with osteoporosis and at high risk of fracture.

Eligibility Criteria

Inclusion

  • Postmenopausal women who can walk freely (≥50 and ≤85 years);
  • The patient has a body mass index(BMI) of 17.0 kg/m2 to 30 kg/m2;
  • The patient has a bone mineral density T-score≤-2.5 and \> -5.0 at the lumbar spine (L1-L4) or femoral neck or total hip by dual energy x-ray absorptiometry (DXA);
  • The patient has at least one of the following high risk factors of fracture: 1) history of previous fragility fractures; 2) family history of hip fragility fracture; 3) age≥70 years; 4) BMI≤19.0 kg/m2;5) Currently smoking.
  • The patient with at least 2 consecutive vertebrae(L1 to L4) and at least 1 hip can be evaluated for BMD.

Exclusion

  • In addition to postmenopausal osteoporosis, the other diseases affecting bone metabolism;
  • History of osteosarcoma;
  • History of orthostatic hypotension;
  • Currently suffering from active urinary calculus;
  • Received anti-osteoporosis treatment that does not meet protocol requirements;
  • Received medication that affects bone metabolism within 4 weeks prior to screening, or is planned to use prohibited drugs/non-drug therapy under the protocol during the study period.

Key Trial Info

Start Date :

June 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 1 2027

Estimated Enrollment :

282 Patients enrolled

Trial Details

Trial ID

NCT06898060

Start Date

June 1 2025

End Date

May 1 2027

Last Update

March 27 2025

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture | DecenTrialz